The US Food and Drug Administration (FDA) on Monday approved a new drug against respiratory syncytial virus (RSV) for newborns and infants. The monoclonal antibodyBeyfortus(nirsevimab-alip), which already is approved for use in Europe and Canada, is indicated for newborns and infants born durin...
The benefits of the RSV vaccine in older adults continue to outweigh the small documented risk of Guillain-Barre syndromeopens in a new tab or window that was linked with the vaccine, Michael Melgar, MD, co-lead of the Adult RSV Work Group, said in a presentation. "Bottom line, preventabl...